1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors

The study assessing the safety, tolerability and preliminary efficacy for KN026 in combination with KN046 in pts with HER2 aberrated solid tumors was reported in the Society for Immunotherapy of Cancer 2020. Here we reported the efficacy and safety in pts with HER2-positive gastrointestinal tumors from expansion phase.